Alzheimer's disease (AD) stands as the predominant form of dementia, presenting significant
and escalating global challenges. Its etiology is intricate and diverse, stemming from a …

Blood-based biomarkers hold great promise to revolutionize the diagnostic and prognostic
work-up of Alzheimer's disease (AD) in clinical practice. This is very timely, considering the …

Abstract The National Institute on Aging and the Alzheimer's Association convened three
separate work groups in 2011 and single work groups in 2012 and 2018 to create …

Plasma phosphorylated tau 181 (P-tau181) and 217 (P-tau217) are indicators of both
amyloid and tau pathology in clinical settings, but their performance in heterogeneous …

High-throughput proteomics platforms measuring thousands of proteins in plasma combined
with genomic and phenotypic information have the power to bridge the gap between the …

Blood-based biomarkers for amyloid beta and phosphorylated tau show good diagnostic
accuracies and agreements with their corresponding CSF and neuroimaging biomarkers in …

Blood‐based markers (BBMs) have recently shown promise to revolutionize the diagnostic
and prognostic work‐up of Alzheimer's disease (AD), as well as to improve the design of …

Importance Plasma biomarkers of Alzheimer disease may be useful as minimally invasive
pharmacodynamic measures of treatment outcomes. Objective To analyze the association of …

Purpose Long COVID, also known as post-acute sequelae of COVID-19, refers to the
constellation of long-term symptoms experienced by people suffering persistent symptoms …

Recent Aβ-immunotherapy trials have yielded the first clear evidence that removing
aggregated Aβ from the brains of symptomatic patients can slow the progression of …